ProtoKinetix Research Pipeline
Join us on our research journey
The proof is in the research
Since 2005, AAGP® has gone through international laboratory testing conducted by some of the best researchers in the world. Backed by years of promising results, data-to-date have shown that AAGP® is non-toxic, stable and effective in keeping cells alive.
We are working to move regenerative medicine forward by addressing health conditions, such as macular degeneration, Type 1 diabetes, heart disease, stroke and so much more. See where we are today and where we are heading next.
The pipeline
Ophthalmology
Dermatology
Transplant support
Biomanufacturing
Promising AAGP® findings
In a clinical setting, AAGP® is showing its ability to protect cells from inflammation, repair and replace damaged cells and improve cell survivability over time.
Enhances the curative potential for Type-1 diabetes by protecting islet cell transplants - Explore the research 
Effectively defends induced pluripotent stem cells (iPSCs) to regenerate retinas and restore vision - Explore the research
Works as a dual agent to protect and recover skin before and after ultraviolet (UV) radiation - Explore the research
Defends tear-producing cells to stop dry eye disease - Explore the research
Preserves cell viability during cryostorage and biosimilar production - Explore the research
Our Patents
ProtoKinetix is proudly patented for the use of AAGP® in a variety of clinical research applications.
Research partners
Since 2005, AAGP® has gone through international laboratory testing conducted by some of the top researchers in the world. See their scientific contributions.
Invest with us
Become part of the next great medical discovery. ProtoKinetix has harnessed a molecule found in nature with the power to change lives through cell survival.
Join us on our journey of cell survival
Get company news and research updates sent directly to your inbox.
ProtoKinetix, Inc.